A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer.

ABSTRACT:

Background

70%-80% of prostate cancer (PCa) biopsies performed in the US annually may be unnecessary. Specific antigen testing (PSA) and tans rectal ultrasound (TRUS) are imprecise predictive methods for risk of PCa. Novel strategies are critical to guide biopsy decision-making.

Aim

We assessed the utility and accuracy of combining Select MDx and multiparametric magnetic resonance imaging (mpMRI) scores for predicting risk of PCa.

Methods and results

Our study was conducted at Mount Sinai hospital at Urology department in New York City from January 2020 to April 2021. Total 129 men performed select MDx test. Indications for prostate biopsy were high-risk Select MDx score, suspicious DRE, PI-RADS scores 3/4/5 on mpMRI, or any combination of these. Fifty-one percentage

SUBMITTER: Wagaskar VG 

PROVIDER: S-EPMC9875685 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature